NCT02471651 - Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 24, 2018

Study Completion Date

October 24, 2018

Conditions

Diabetic Macular Edema

Interventions

DRUG

Dexamethasone intravitreal implant (0.7 mg)

Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).

DRUG

Intravitreal anti-VEGF injection

This injection may be ranibizumab, bevacizumab, or aflibercept.

Trial Locations (4)

California Retina Consultants, Oxnard

California Retina Consultants, Santa Barbara

California Retina Consultants, Bakersfield

California Retina Consultants, Santa Maria